Arch Therapeutics (ARTH) 10-Q 13 May 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Mar. 31, 2022	May 13, 2022
Document Information [Line Items]
Entity Central Index Key	0001537561
Entity Registrant Name	Arch Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-54986
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	46-0524102
Entity Address, Address Line One	235 Walnut Street, Suite 6
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01702
City Area Code	617
Local Phone Number	431-2313
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		237,069,770

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2022	Sep. 30, 2021
Cash	$ 54,405	$ 2,266,639
Inventory	1,197,568	1,093,765
Prepaid expense and other current assets	180,261	307,341
Total current assets	1,432,234	3,667,745
Long-term assets:
Property and equipment, net	3,642	5,240
Other assets	3,500	3,500
Total long-term assets	7,142	8,740
Total assets	1,439,376	3,676,485
Current liabilities:
Accounts payable	1,288,078	408,083
Accrued expense and other liabilities	156,329	319,464
Current portion of derivative liability	0	1,000,000
Total current liabilities	1,444,407	1,727,547
Long-term liabilities:
Accrued interest	246,918	167,137
Derivative liability, net of current portion	1,207,475	1,207,475
Total long-term liabilities	3,054,393	2,974,612
Total liabilities	4,498,800	4,702,159
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.001 par value, 800,000,000 shares authorized; 237,169,770 shares issued as of March 31, 2022 and September 30, 2021 and 237,069,770 and 236,719,770 shares outstanding as of March 31, 2022 and September 30, 2021	236,920	236,720
Additional paid-in capital	48,841,040	48,534,525
Accumulated deficit	(52,137,384)	(49,796,919)
Total stockholders’ deficit	(3,059,424)	(1,025,674)
Total liabilities and stockholders’ deficit	1,439,376	3,676,485
Series 1 Convertible Notes [Member]
Long-term liabilities:
Convertible notes	550,000	550,000
Series 2 Convertible Notes [Member]
Long-term liabilities:
Convertible notes	$ 1,050,000	$ 1,050,000

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2022	Sep. 30, 2021
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	800,000,000	800,000,000
Common stock, shares issued (in shares)	237,169,770	237,169,770
Common stock, shares outstanding (in shares)	237,069,770	236,719,770

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenue	$ 3,130	$ 10,000	$ 7,826	$ 10,000
Operating expense:
Cost of revenues	17,430	10,102	34,223	10,102
Selling, general and administrative expense	1,208,910	1,339,833	2,472,013	2,230,024
Research and development expense	527,656	410,611	762,274	754,202
Total costs and expenses	1,753,996	1,760,546	3,268,510	2,994,328
Loss from operations	(1,750,866)	(1,750,546)	(3,260,684)	(2,984,328)
Other income (expense):
Interest expense	(39,452)	(40,750)	(79,781)	(70,016)
Decrease to fair value of derivative liability	1,000,000	0	1,000,000	108,944
Total other income (expense)	960,548	(40,750)	920,219	38,928
Net loss	$ (790,318)	$ (1,791,296)	$ (2,340,465)	$ (2,945,400)
Loss per share - basic and diluted
Net loss per common share - basic and diluted (in dollars per share)	$ 0	$ (0.01)	$ (0.01)	$ (0.01)
Weighted common shares - basic and diluted (in shares)	236,865,603	213,337,625	236,806,034	203,135,751

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Sep. 30, 2020	193,044,766
Balance at Sep. 30, 2020	$ 193,045	$ 41,862,901	$ (43,556,437)	$ (1,500,491)
Net loss	$ 0	0	(2,945,400)	(2,945,400)
Vesting of Restricted Stock (in shares)	550,000
Vesting of Restricted Stock	$ 550	(550)		0
Stock-based compensation expense	$ 0	278,340	0	278,340
Balance (in shares) at Mar. 31, 2021	236,719,770
Balance at Mar. 31, 2021	$ 236,720	48,316,799	(46,501,837)	2,051,682
Issuance of common stock and warrants, net of financing costs (in shares)	43,125,004
Issuance of common stock and warrants, net of financing costs	$ 43,125	6,176,108	0	6,219,233
Balance (in shares) at Dec. 31, 2020	193,044,766
Balance at Dec. 31, 2020	$ 193,045	41,948,512	(44,710,541)	(2,568,984)
Net loss	$ 0	0	(1,791,296)	(1,791,296)
Vesting of Restricted Stock (in shares)	550,000
Vesting of Restricted Stock	$ 550	(550)		0
Stock-based compensation expense	$ 0	192,729	0	192,729
Balance (in shares) at Mar. 31, 2021	236,719,770
Balance at Mar. 31, 2021	$ 236,720	48,316,799	(46,501,837)	2,051,682
Issuance of common stock and warrants, net of financing costs (in shares)	43,125,004
Issuance of common stock and warrants, net of financing costs	$ 43,125	6,176,108	0	6,219,233
Balance (in shares) at Sep. 30, 2021	236,719,770
Balance at Sep. 30, 2021	$ 236,720	48,534,525	(49,796,919)	(1,025,674)
Net loss	$ 0	0	(2,340,465)	(2,340,465)
Vesting of Restricted Stock (in shares)	200,000
Vesting of Restricted Stock	$ 200	(200)	0	0
Stock-based compensation expense	$ 0	306,715	0	306,715
Balance (in shares) at Mar. 31, 2022	236,919,770
Balance at Mar. 31, 2022	$ 236,920	48,841,040	(52,137,384)	(3,059,424)
Balance (in shares) at Dec. 31, 2021	236,794,770
Balance at Dec. 31, 2021	$ 236,795	48,686,593	(51,347,066)	(2,423,678)
Net loss	$ 0	0	(790,318)	(790,318)
Vesting of Restricted Stock (in shares)	125,000
Vesting of Restricted Stock	$ 125	(125)	0	0
Stock-based compensation expense	$ 0	154,572	0	154,572
Balance (in shares) at Mar. 31, 2022	236,919,770
Balance at Mar. 31, 2022	$ 236,920	$ 48,841,040	$ (52,137,384)	$ (3,059,424)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (2,340,465)	$ (2,945,400)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	1,598	989
Stock-based compensation	306,715	278,340
Decrease to fair value of derivative liability	(1,000,000)	(108,944)
Inventory obsolescence charge	248,073	181,988
Changes in operating assets and liabilities:
Inventory	(351,876)	(42,215)
Prepaid expense and other current assets	127,080	(237,703)
Accounts payable	879,995	216,783
Accrued interest	79,781	69,137
Accrued expense and other liabilities	(163,135)	(77,426)
Net cash used in operating activities	(2,212,234)	(2,664,451)
Cash flows from investing activities:
Purchases of property and equipment	0	(3,275)
Net cash used in investing activities	0	(3,275)
Cash flows from financing activities:
Proceeds received from convertible notes	0	1,050,000
Proceeds from issued common stock and warrants, net of financing costs	0	6,219,233
Net cash provided by financing activities	0	7,269,233
Net increase (decrease) in cash	(2,212,234)	4,601,507
Cash, beginning of period	2,266,639	959,309
Cash, end of period	54,405	5,560,816
Non-cash financing activities:
Issuance of restricted stock for services	$ 19,887	$ 103,750

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Description of Business	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Organization and Description of Business Arch Therapeutics, Inc., (together with its subsidiary, the “ Company Arch September 16, 2009, June 26, 2013, Merger ABS Merger Sub ABS was incorporated under the laws of the Commonwealth of Massachusetts on March 6, 2006, April 7, 2008, The Company commenced commercial sales of our first AC5® three March 31, 2021, Common Stock The Company expects to incur substantial expenses for the foreseeable future relating to research, development and commercialization of its potential products. However, there can be no not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“ US GAAP Although the Company believes that the disclosures in these unaudited interim consolidated financial statements are adequate to make the information presented not SEC 10 September 30, 2021, December 17, 2021. For a complete summary of the Company’s significant accounting policies, please refer to Note 2 8 10 September 30, 2021. no six March 31, 2022. Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three March 31, 2022 September 30, 2021. Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred. Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment three six March 31, 2022 2021 not Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ ROU not Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense. Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred. Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation FASB ASC Topic 718 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At March 31, 2022 September 30, 2021, Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. In particular, as of March 31, 2022, may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not

Note 3 - Property and Equipment

Note 3 - Property and Equipment	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. At March 31, 2022 September 30, 2021, Estimated Useful March 31, September 30, Life (years) 2022 2021 Computer equipment 3 $ 9,357 $ 9,357 Furniture and fixtures 5 8,983 8,983 Leasehold improvements Life of Lease 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,114 28,516 Property and equipment, net $ 3,642 $ 5,240 For the three March 31, 2022 2021, six March 31, 2022 2021

Note 4 - Inventories

Note 4 - Inventories	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	4 INVENTORIES Inventories consist of the following: March 31, September 30, 2022 2021 Finished Goods $ - $ 249,571 Goods-in-process 1,197,568 844,194 Total $ 1,197,568 $ 1,093,765 The Company capitalizes inventory that has been produced for commercial sale and has been determined to have a probable future economic benefit. The determination of whether or not

Note 5 - Stock-based Compensati

Note 5 - Stock-based Compensation	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	5. 2013 On June 18, 2013, 2013 2013 2013 September 30, 2021, may one two 2013 first 2014, 2013 3,000,000 four 4 Board October 1, 2021, The exercise price of each option is equal to the closing price of a share of our Common Stock on the date of grant. Share-Based awards During the six March 31, 2022, 2013 . Share-based compensation expense for awards granted during the three March 31, 2022 Common Stock Options Stock compensation activity under the 2013 six March 31, 2022 Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 250,000 0.10 — — Forfeited/Cancelled (2,716,917 ) 0.35 — — Outstanding at March 31, 2022 22,432,097 0.28 1.61 1,750 Vested at March 31, 2022 18,733,501 0.32 1.83 52 Vested and expected to vest at March 31, 2022 22,432,097 0.28 1.61 1,750 As of March 31, 2022, 2013 three March 31, 2022 2021 three March 31, 2022 2021, six March 31, 2022 2021 six March 31, 2022 2021, During the six March 31, 2022 2021, As of March 31, 2022, 2013 Restricted Stock Restricted Stock activity in shares under the 2013 three March 31, 2022 2021 Three Months Ended March 31, 2022 March 31, 2021 Shares Weighted Average Grant Date Fair Value Shares Weighted Average Grant Date Fair Value Non Vested at December 31, 2021 and 2020 375,000 $ 0.10 50,000 $ 0.18 Awarded — — 500,000 0.19 Vested (125,000 ) 0.10 (550,000 ) (0.19 ) Forfeited — — — — Non Vested at March 31, 2022 and 2021 250,000 $ 0.10 — $ — Restricted Stock activity in shares under the 2013 six March 31, 2022 2021 Six Months Ended March 31, 2022 March 31, 2021 Shares Weighted Average Grant Date Fair Value Shares Weighted Average Grant Date Fair Value Non Vested at September 30, 2021 and 2020 450,000 $ 0.10 — $ — Awarded — — 550,000 0.19 Vested (200,000 ) 0.10 (550,000 ) (0.19 ) Forfeited — — — — Non Vested at March 31, 2022 and 2021 250,000 $ 0.10 — $ — For the three March 31, 2022 2021, six March 31, 2022 2021,

Note 6 - Registered Direct Offe

Note 6 - Registered Direct Offerings That Created Derivative Liabilities	6 Months Ended
	Mar. 31, 2022
Registered Direct Offerings [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. On September 30, 2016, October 20, 2016 Shelf Registration Statement may On February 20, 2017, 2017 six 2017 2017 2017 2017 fifth 2017 2017 2017 On June 28, 2018, 2018 eight 2018 2018 2018 2018 fifth 2018 2018 On May 12, 2019, 2019 five 2019 2019 2019 2019 one fifth 2019 2019 2019 During the three six March 31, 2022 2021, March 31, 2022, 6,802,500 may three March 31, 2022,

Note 7 - Derivative Liabilities

Note 7 - Derivative Liabilities	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	7. The Company accounted for the Series F Warrants relating to the 2017 2018 2019 815 10, Derivatives and Hedging may Minimum not On the respective closing dates, the Series F, Series G and Series H derivative liabilities were recorded at an aggregate fair value of $1,628,113. Given that the fair value of the derivative liabilities were less than the net proceeds, the remaining proceeds were allocated to Common Stock and additional-paid-in-capital. During the three March 31, 2022 2021, six March 31, 2022 2021, three March 31, 2022, Fair Value Measurements Using Significant Unobservable Inputs - March 31, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value (1,000,000 ) — — Ending balance at March 31, 2022 $ — $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances — — — Adjustments to estimated fair value — — (108,944 ) Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 The derivative liabilities were valued as of March 31, 2022 Series F Series G Series H Closing price per share of Common Stock $ — $ 0.0975 $ 0.0975 Exercise price per share $ — $ 0.70 $ 0.40 Expected volatility (missing info?) — % 108.22 % 95.71 % Risk-free interest rate — % 1.63 % 2.28 % Dividend yield — — — Remaining expected term of underlying securities (years) — 1.19 2.08 The derivative liabilities were valued as of September 30, 2021 Series F Series G Series H Closing price per share of Common Stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.70 $ 0.40 Expected volatility 90.28 % 87.40 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.70 2.58

Note 8 - October 2019 Registere

Note 8 - October 2019 Registered Direct Offering	6 Months Ended
	Mar. 31, 2022
October 2019 Registered Direct Offering [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. OCTOBER 2019 On October 16, 2019, October 2019 seven October 2019 2019 October 2019 Financing October 2019 fifth October 2019 October 2019 October 2019 Shares October 18, 2019, 14,285,714 Placement Agent Warrants five The gross proceeds to Arch from the October 2019 October 18, 2019, We engaged H.C. Wainwright (“ Wainwright October Engagement Agreement October 10, 2019, $2.5 $158,000. During the six March 31, 2022 2021, March 31, 2022, may Common Stock On October 18, 2019 October 2019 14,285,714 Equity Value of Warrants The Company accounted for the Series I Warrants and the Placement Agent Warrants relating to the aforementioned October 2019 815 40, Derivatives and Hedging

Note 9 - 2021 Registered Direct

Note 9 - 2021 Registered Direct Offering	6 Months Ended
	Mar. 31, 2022
The 2021 Registered Direct Offering [Member]
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. 2021 On February 11, 2021, 2021 2021 2021 Shares Series K Warrants Warrant Shares 2021 Engagement Agreement February 8, 2021, Placement Agent 2021 one Placement Agent 2 2 2 The 2021 2021 February 11, 2022; may The number of shares of the Company’s Common Stock into which each of the Series K Warrants is exercisable and the exercise price therefore are subject to adjustment, as set forth in the Series K Warrants, including adjustments for stock subdivisions or combinations (by any stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise). During the six March 31, 2022, 2 March 31, 2022, may Common Stock On February 17, 2021 2021 43,125,004 Equity Value of Warrants The Company accounted for the Series K Warrants and the Placement Agent 2 February 2021 815 40, Derivatives and Hedging 2

Note 10 - Convertible Notes

Note 10 - Convertible Notes	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	10. On June 4, 2020 November 6, 2020, 1 Series 1 2 Series 2 1 2 June 30, 2023 November 30, 2023, 1 2 three 1 2 not Conversion Price 1 2 Holder VWAP fifteen 15 In-Kind Note Repayment thirty-five 35% ten 10% twelve ten March 31, 2022, 1 2 thirty-five 35% sixty 60% On June 3, 2020, Agreement Majority Holder s Warrant June 4, 2020, 1 November 6, 2020, one 1 thirty On June 22, 2020, Keyes Sulat Agreement Trust June 22, 2020, one During the three March 31, 2022 2021, six March 31, 2022 2021,

Note 11 - Payroll Protection Pr

Note 11 - Payroll Protection Program Loan	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	10. On June 4, 2020 November 6, 2020, 1 Series 1 2 Series 2 1 2 June 30, 2023 November 30, 2023, 1 2 three 1 2 not Conversion Price 1 2 Holder VWAP fifteen 15 In-Kind Note Repayment thirty-five 35% ten 10% twelve ten March 31, 2022, 1 2 thirty-five 35% sixty 60% On June 3, 2020, Agreement Majority Holder s Warrant June 4, 2020, 1 November 6, 2020, one 1 thirty On June 22, 2020, Keyes Sulat Agreement Trust June 22, 2020, one During the three March 31, 2022 2021, six March 31, 2022 2021,
Paycheck Protection Program Loan [Member]
Notes to Financial Statements
Debt Disclosure [Text Block]	11. On April 25, 2020, PPP Note PPP Loan PPP CARES Act SBA Lender The PPP Loan had a two 1.00% not $20,000 The PPP Note contained customary events of default relating to, among other things, payment defaults, providing materially false and misleading representations to the SBA or Lender, or breaching the terms of the PPP Loan documents. The occurrence of an event of default would have resulted in the immediate repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment. Under the terms of the CARES Act, PPP Loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. During November 2020, May 28, 2021, The SBA reserves the right to audit any PPP loan, regardless of size. These audits may six

Note 12 - Risks and Uncertainti

Note 12 - Risks and Uncertainties - COVID-19 and Geopolitical Conflicts	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
COVID-19 Disclsoure [Text Block]	12. COVID- 19 The Company sources its materials and services for its products and product candidates from facilities in areas impacted or which may may may

Note 13 - Subsequent Events

Note 13 - Subsequent Events	6 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	13. SUBSEQUENT EVENTS The Company evaluated all events or transactions through May 13, 2022 no Effective as of the date of this filing, the Company has raised $460,000 toward the first first

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements include the accounts of Arch Therapeutics, Inc. and its wholly owned subsidiary, Arch Biosurgery, Inc., a biotechnology company. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three March 31, 2022 September 30, 2021.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value. The cost of inventories comprises expenditures incurred in acquiring the inventories, the cost of conversion and other costs incurred in bringing them to their existing location and condition. The cost of raw materials, goods-in-process and finished goods are determined on a First in First out (FiFo) basis. When determining net realizable value, appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may not not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the related asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in income or loss for the period. Repair and maintenance expenditures are charged to expense as incurred.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment when circumstances indicate the carrying value of an asset may not 360, Property, Plant and Equipment three six March 31, 2022 2021 not
Lessee, Leases [Policy Text Block]	Leases The Company determines if an arrangement is a lease at its inception. Operating lease right-of-use (“ ROU not
Income Tax, Policy [Policy Text Block]	Income Taxes In accordance with FASB ASC 740, Income Taxes not not The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is more likely than not
Revenue from Contract with Customer [Policy Text Block]	Revenue In accordance with FASB ASC 606, Revenue Recognition five The Company’s source of revenue is product sales. Contracts with customers contain a single performance obligation and the Company recognizes revenue from product sales when the Company has satisfied our performance obligation by transferring control of the product to the customers. Control of the product transfers to the customer upon shipment from the Company’s third
Cost of Goods and Service [Policy Text Block]	Cost of Revenue Cost of revenue includes product costs, warehousing, overhead allocation and royalty expense.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company expenses internal and external research and development costs, including costs of funded research and development arrangements, in the period incurred.
Share-Based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation The Company accounts for stock-based compensation in accordance with the guidance of FASB ASC Topic 718, Compensation-Stock Compensation FASB ASC Topic 718 718, The determination of the fair value of share-based payment awards utilizing the Black-Scholes model is affected by the fair value of the Common Stock and a number of other assumptions, including expected volatility, expected life, risk-free interest rate and expected dividends. The expected life for awards uses the simplified method for all “plain vanilla” options, as defined in ASC 718 10 S99 no
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company measures both financial and nonfinancial assets and liabilities in accordance with FASB ASC Topic 820, Fair Value Measurements and Disclosures three 1 2 1 3 At March 31, 2022 September 30, 2021,
Derivatives, Policy [Policy Text Block]	Derivative Liabilities The Company accounts for its warrants and other derivative financial instruments as either equity or liabilities based upon the characteristics and provisions of each instrument, in accordance with FASB ASC Topic 815, Derivatives and Hedging no
Going Concern [Policy Text Block]	Going Concern Basis of Accounting As reflected in the consolidated financial statements, the Company has an accumulated deficit, has suffered significant net losses and negative cash flows from operations, only recently commenced generating limited operating revenues, and has limited working capital. The continuation of the Company’s business as a going concern is dependent upon raising additional capital, the ability to successfully market and sell its product(s) and eventually attaining and maintaining profitable operations. In particular, as of March 31, 2022, may APIs AC5® June 28, 2018 (“ 2018 2018 not 2018 20% 2018 The continued spread of coronavirus and geopolitical conflicts, including the recent war in Ukraine, as well as uncertain market conditions, may may The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The consolidated financial statements do not

Note 3 - Property and Equipme_2

Note 3 - Property and Equipment (Tables)	6 Months Ended
	Mar. 31, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	Estimated Useful March 31, September 30, Life (years) 2022 2021 Computer equipment 3 $ 9,357 $ 9,357 Furniture and fixtures 5 8,983 8,983 Leasehold improvements Life of Lease 14,416 14,416 Lab equipment 5 1,000 1,000 33,756 33,756 Less – accumulated depreciation 30,114 28,516 Property and equipment, net $ 3,642 $ 5,240

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	6 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, September 30, 2022 2021 Finished Goods $ - $ 249,571 Goods-in-process 1,197,568 844,194 Total $ 1,197,568 $ 1,093,765

Note 5 - Stock-based Compensa_2

Note 5 - Stock-based Compensation (Tables)	6 Months Ended
	Mar. 31, 2022
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Option Shares Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value Outstanding at September 30, 2021 24,899,014 $ 0.29 1.83 $ 140,151 Awarded 250,000 0.10 — — Forfeited/Cancelled (2,716,917 ) 0.35 — — Outstanding at March 31, 2022 22,432,097 0.28 1.61 1,750 Vested at March 31, 2022 18,733,501 0.32 1.83 52 Vested and expected to vest at March 31, 2022 22,432,097 0.28 1.61 1,750
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	— Three Months Ended March 31, 2022 March 31, 2021 Shares Weighted Average Grant Date Fair Value Shares Weighted Average Grant Date Fair Value Non Vested at December 31, 2021 and 2020 375,000 $ 0.10 50,000 $ 0.18 Awarded — — 500,000 0.19 Vested (125,000 ) 0.10 (550,000 ) (0.19 ) Forfeited — — — — Non Vested at March 31, 2022 and 2021 250,000 $ 0.10 — $ — Six Months Ended March 31, 2022 March 31, 2021 Shares Weighted Average Grant Date Fair Value Shares Weighted Average Grant Date Fair Value Non Vested at September 30, 2021 and 2020 450,000 $ 0.10 — $ — Awarded — — 550,000 0.19 Vested (200,000 ) 0.10 (550,000 ) (0.19 ) Forfeited — — — — Non Vested at March 31, 2022 and 2021 250,000 $ 0.10 — $ —

Note 7 - Derivative Liabiliti_2

Note 7 - Derivative Liabilities (Tables)	6 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Fair Value Measurements Using Significant Unobservable Inputs - March 31, 2022 (Level 3) Series F Series G Series H Beginning balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200 Issuances — — — Adjustments to estimated fair value (1,000,000 ) — — Ending balance at March 31, 2022 $ — $ 748,275 $ 459,200 Fair Value Measurements Using Significant Unobservable Inputs September 30, 2021 (Level 3) Series F Series G Series H Beginning balance at September 30, 2020 $ 1,000,000 $ 748,275 $ 568,144 Issuances — — — Adjustments to estimated fair value — — (108,944 ) Ending balance at September 30, 2021 $ 1,000,000 $ 748,275 $ 459,200
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Series F Series G Series H Closing price per share of Common Stock $ — $ 0.0975 $ 0.0975 Exercise price per share $ — $ 0.70 $ 0.40 Expected volatility (missing info?) — % 108.22 % 95.71 % Risk-free interest rate — % 1.63 % 2.28 % Dividend yield — — — Remaining expected term of underlying securities (years) — 1.19 2.08 Series F Series G Series H Closing price per share of Common Stock $ 0.12 $ 0.12 $ 0.12 Exercise price per share $ 0.75 $ 0.70 $ 0.40 Expected volatility 90.28 % 87.40 % 86.59 % Risk-free interest rate 0.04 % 0.19 % 0.41 % Dividend yield — — — Remaining expected term of underlying securities (years) 0.34 1.70 2.58

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Description of Business (Details Textual) - $ / shares	Mar. 31, 2022	Sep. 30, 2021
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2021
Cash Equivalents, at Carrying Value, Total	$ 0		$ 0		$ 0
Asset Impairment Charges, Total	$ 0	$ 0	$ 0	$ 0

Note 3 - Property and Equipme_3

Note 3 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Depreciation, Total	$ 799	$ 617	$ 1,598	$ 989

Note 3 - Property and Equipme_4

Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	6 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Property and equipment, gross	$ 33,756	$ 33,756
Less – accumulated depreciation	30,114	28,516
Property and equipment, net	$ 3,642	5,240
Computer Equipment [Member]
Estimated useful life (Year)	3 years
Property and equipment, gross	$ 9,357	9,357
Furniture and Fixtures [Member]
Estimated useful life (Year)	5 years
Property and equipment, gross	$ 8,983	8,983
Leasehold Improvements [Member]
Property and equipment, gross	$ 14,416	14,416
Equipment [Member]
Estimated useful life (Year)	5 years
Property and equipment, gross	$ 1,000	$ 1,000

Note 4 - Inventories (Details)

Note 4 - Inventories (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Finished Goods		$ 0		$ 249,571
Goods-in-process		1,197,568		844,194
Total	$ 1,197,568	$ 1,197,568	$ 1,093,765	$ 1,093,765

Note 5 - Stock-based Compensa_3

Note 5 - Stock-based Compensation (Details Textual) - USD ($)	Oct. 01, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 18, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)				0	0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 48,000		$ 48,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 2 months 4 days
Restricted Stock [Member]
Share-Based Payment Arrangement, Expense		$ 10,000	$ 104,000	$ 20,000	$ 104,000
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	34,114,256					31,114,256
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		5,566,257		5,566,257
Share-Based Payment Arrangement, Expense		$ 145,000	89,000	$ 287,000	174,000
The 2013 Plan [Member] | Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense		41,000	27,000	94,000	53,000
The 2013 Plan [Member] | General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense		$ 104,000	$ 62,000	$ 193,000	$ 121,000
The 2013 Plan [Member] | Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				250,000
The 2013 Plan [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				0

Note 5 - Stock-based Compensa_4

Note 5 - Stock-based Compensation - Stock Compensation Activity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Outstanding (in shares)	24,899,014
Outstanding, weighted average exercise price (in dollars per share)	$ 0.29
Outstanding, weighted average remaining contractual term (Year)	1 year 7 months 9 days	1 year 9 months 29 days
Outstanding, aggregate intrinsic value	$ 1,750	$ 140,151
Awarded (in shares)	250,000
Awarded, weighted average exercise price (in dollars per share)	$ 0.10
Forfeited/Cancelled (in shares)	(2,716,917)
Forfeited/Cancelled, weighted average exercise price (in dollars per share)	$ 0.35
Outstanding (in shares)	22,432,097	24,899,014
Outstanding, weighted average exercise price (in dollars per share)	$ 0.28	$ 0.29
Vested (in shares)	18,733,501
Vested, weighted average exercise price (in dollars per share)	$ 0.32
Vested, weighted average remaining contractual term (Year)	1 year 9 months 29 days
Vested and expected to vest (in shares)	22,432,097
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.28
Vested and expected to vest, weighted average remaining contractual term (Year)	1 year 7 months 9 days
Vested and expected to vest, aggregate intrinsic value	$ 1,750

Note 5 - Stock-based Compensa_5

Note 5 - Stock-based Compensation - Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Non Vested, shares (in shares)	375,000	50,000	450,000	0
Non Vested, weighted average fair value (in dollars per share)	$ 0.10	$ 0.18	$ 0.10	$ 0
Awarded, shares (in shares)	0	500,000	0	550,000
Awarded, weighted average fair value (in dollars per share)	$ 0	$ 0.19	$ 0	$ 0.19
Vested, shares (in shares)	(125,000)	(550,000)	(200,000)	(550,000)
Vested, weighted average fair value (in dollars per share)	$ 0.10	$ 0.19	$ 0.10	$ 0.19
Vested, weighted average fair value (in dollars per share)	$ (0.10)	$ (0.19)	$ (0.10)	$ (0.19)
Forfeited, shares (in shares)	0	0	0	0
Forfeited, weighted average fair value (in dollars per share)	$ 0	$ 0	$ 0	$ 0
Non Vested, shares (in shares)	250,000	0	250,000	0
Non Vested, weighted average fair value (in dollars per share)	$ 0.10	$ 0	$ 0.10	$ 0

Note 6 - Registered Direct Of_2

Note 6 - Registered Direct Offerings That Created Derivative Liabilities (Details Textual) - USD ($)	May 12, 2019	Jun. 28, 2018	Feb. 20, 2017	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Sep. 30, 2016
Series F Warrant [Member]
Warrants and Rights, Percent of Stock Oustanding Callable			55.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.75
Class of Warrant or Right, Expired During Period (in shares)				5,591,664
Series G Warrant [Member]
Warrants and Rights, Percent of Stock Oustanding Callable		75.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.70
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				6,802,500		6,802,500
Series H Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				8,615,384		8,615,384
Series F, Series G, and Series H Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)				0	0	0	0
The 2017 SPA [Member]
Registered Direct Offering, Maximum Amount								$ 50,000,000
Stock Issued During Period, Shares, New Issues (in shares)			10,166,664
Shares Issued, Price Per Share (in dollars per share)			$ 0.60
The 2018 SPA [Member]
Stock Issued During Period, Shares, New Issues (in shares)		9,070,000
Shares Issued, Price Per Share (in dollars per share)		$ 0.50
The 2019 SPA [Member]
Stock Issued During Period, Shares, New Issues (in shares)	8,615,384
Shares Issued, Price Per Share (in dollars per share)	$ 0.325

Note 7 - Derivative Liabiliti_3

Note 7 - Derivative Liabilities (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Derivative Warrant Liability [Member]
Derivative Liability, Total	$ 1,628,113		$ 1,628,113
Fair Value Adjustment of Derivatives	$ 1,000,000	$ 0	$ 1,000,000	$ 108,944
Series F Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	$ 0.18		$ 0.18
Series G Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	0.11		0.11
Series H Warrant [Member]
Class of Warrants and Rights, Required Cash Purchase Price (in dollars per share)	$ 0.0533		$ 0.0533

Note 7 - Derivative Liabiliti_4

Note 7 - Derivative Liabilities - Fair Value of Derivative Liability (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Sep. 30, 2021
Issuances	$ 0
Series F Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Balance	1,000,000	$ 1,000,000
Issuances		0
Adjustments to estimated fair value	(1,000,000)	0
Balance	0	1,000,000
Series G Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Balance	748,275	748,275
Issuances		0
Adjustments to estimated fair value	0	0
Balance	748,275	748,275
Series H Warrant Derivative [Member] | Fair Value, Inputs, Level 3 [Member] | Derivative Financial Instruments, Liabilities [Member]
Balance	459,200	568,144
Issuances		0
Adjustments to estimated fair value	0	(108,944)
Balance	$ 459,200	$ 459,200

Note 7 - Derivative Liabiliti_5

Note 7 - Derivative Liabilities - Derivative Liability Value Assumptions (Details) - Derivative Financial Instruments, Liabilities [Member]	Mar. 31, 2022	Sep. 30, 2021
Series F Warrant Derivative [Member] | Measurement Input, Share Price [Member]
Derivative Liability, Measurement Input	0	0.12
Series F Warrant Derivative [Member] | Measurement Input, Exercise Price [Member]
Derivative Liability, Measurement Input	0	0.75
Series F Warrant Derivative [Member] | Measurement Input, Price Volatility [Member]
Derivative Liability, Measurement Input	0	0.9028
Series F Warrant Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input	0	0.0004
Series F Warrant Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Derivative Liability, Measurement Input	0	0
Series F Warrant Derivative [Member] | Measurement Input, Expected Term [Member]
Derivative Liability, Measurement Input	0	0.34
Series G Warrant Derivative [Member] | Measurement Input, Share Price [Member]
Derivative Liability, Measurement Input	0.0975	0.12
Series G Warrant Derivative [Member] | Measurement Input, Exercise Price [Member]
Derivative Liability, Measurement Input	0.70	0.70
Series G Warrant Derivative [Member] | Measurement Input, Price Volatility [Member]
Derivative Liability, Measurement Input	1.0822	0.8740
Series G Warrant Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input	0.0163	0.0019
Series G Warrant Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Derivative Liability, Measurement Input	0	0
Series G Warrant Derivative [Member] | Measurement Input, Expected Term [Member]
Derivative Liability, Measurement Input	1.19	1.70
Series H Warrant Derivative [Member] | Measurement Input, Share Price [Member]
Derivative Liability, Measurement Input	0.0975	0.12
Series H Warrant Derivative [Member] | Measurement Input, Exercise Price [Member]
Derivative Liability, Measurement Input	0.40	0.40
Series H Warrant Derivative [Member] | Measurement Input, Price Volatility [Member]
Derivative Liability, Measurement Input	0.9571	0.8659
Series H Warrant Derivative [Member] | Measurement Input, Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input	0.0228	0.0041
Series H Warrant Derivative [Member] | Measurement Input, Expected Dividend Rate [Member]
Derivative Liability, Measurement Input	0	0
Series H Warrant Derivative [Member] | Measurement Input, Expected Term [Member]
Derivative Liability, Measurement Input	2.08	2.58

Note 8 - October 2019 Registe_2

Note 8 - October 2019 Registered Direct Offering (Details Textual) - USD ($)	Oct. 18, 2019	Mar. 31, 2022	Mar. 31, 2021
Series I Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.22
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		14,285,714
October 2019 Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.21875
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,071,429
Warrants and Rights Outstanding, Term (Year)	5 years
Series I and Placement Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)		0	0
Placement Fees [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		1,071,429
October 2019 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	14,285,714
Shares Issued, Price Per Share (in dollars per share)	$ 0.175
Proceeds from Issuance or Sale of Equity, Total	$ 2,500,000
Payments of Stock Issuance Costs	$ 333,000
October 2019 Registered Direct Offering [Member] | Minimum [Member]
Securities Purchase Agreement, Cash Placement Fee	6.00%
October 2019 Registered Direct Offering [Member] | Maximum [Member]
Securities Purchase Agreement, Cash Placement Fee	8.20%
October 2019 Registered Direct Offering [Member] | Placement Fees [Member] | Wainwright [Member]
Payments of Stock Issuance Costs	$ 158,000

Note 9 - 2021 Registered Dire_2

Note 9 - 2021 Registered Direct Offering (Details Textual) - USD ($)	Feb. 17, 2021	Mar. 31, 2022
Series K Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	32,343,754	32,343,754
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.17
Warrants and Rights Outstanding, Term (Year)	5 years 6 months
Placement Agent 2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,234,375	3,234,375
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.20
Warrants and Rights, Percent of Stock Oustanding Callable	7.50%
Series K and Placement Agent 2 Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)		0
The 2021 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	43,125,004
Shares Issued, Price Per Share (in dollars per share)	$ 0.16
Proceeds from Issuance or Sale of Equity, Total	$ 6,900,000
Payments of Stock Issuance Costs	700,000
The 2021 Registered Direct Offering [Member] | Non-accountable Expense Fee [Member]
Securities Purchase Agreement, Potential Fees	10,000
The 2021 Registered Direct Offering [Member] | Fees and Expenses of Legal Counsel and Other Out-of-pocket Expenses [Member]
Securities Purchase Agreement, Potential Fees	50,000
The 2021 Registered Direct Offering [Member] | Clearing Expenses [Member]
Securities Purchase Agreement, Potential Fees	$ 10,000
The 2021 Registered Direct Offering [Member] | Participating Investors [Member]
Securities Purchase Agreement, Cash Placement Fee	7.50%
The 2021 Registered Direct Offering [Member] | Certain Investors With Pre-existing Relationships [Member]
Securities Purchase Agreement, Cash Placement Fee	6.00%

Note 10 - Convertible Notes (De

Note 10 - Convertible Notes (Details Textual) - USD ($)	Jun. 22, 2020	Jun. 04, 2020	Jun. 03, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Nov. 06, 2020
Series D Warrants [Member]
Proceeds from Warrant Exercises	$ 82,000		$ 850,000
Class of Warrant or Right, Warrants Exercised (in shares)	454,546
Remaining Warrants [Member]
Class of Warrant or Right, Warrants Exercised (in shares)		4,727,273
Series J Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	340,910	3,545,454						3,375,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25	$ 0.25
Warrants and Rights Outstanding, Term (Year)	1 year	1 year						30 months
Series 1 Convertible Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Debt Instrument, Face Amount		$ 550,000
Debt Instrument, Term (Year)		3 years
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.27
Debt Instrument, Early Repayment Minimum Interest, Percentage		10.00%
Series 1 Convertible Notes [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.32
Series 2 Convertible Notes [Member]
Debt Instrument, Face Amount								$ 1,050,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 0.25
Series 1 & 2 Convertible Notes [Member]
Interest Expense, Debt, Total				$ 39,000	$ 41,000	$ 80,000	$ 70,000

Note 11 - Payroll Protection _2

Note 11 - Payroll Protection Program Loan (Details Textual)	Apr. 25, 2020USD ($)
Paycheck Protection Program Loan [Member]
Proceeds from Issuance of Debt	$ 176,300

Note 13 - Subsequent Events (De

Note 13 - Subsequent Events (Details Textual) - Subsequent Event [Member]	1 Months Ended
	May 13, 2022USD ($)
Proceeds from Issuance or Sale of Equity, Including Amount in Escrow	$ 460,000
Proceeds from Issuance or Sale of Equity, Total	360,000
Escrow Deposit	100,000
Minimum Closing Amount for Escrow Deposit to be Released	$ 2,000,000